Medipal Posts Higher Sales and Profit, Lifts Dividend but Guides Cautiously for FY2027

An update from Medipal Holdings ( (JP:7459) ) is now available.

Medipal Holdings reported a 4.0% rise in consolidated net sales to ¥3.82 trillion for the fiscal year ended March 31, 2026, while operating profit slipped 4.4% to ¥53.2 billion but ordinary profit climbed 16.0% and profit attributable to owners of parent rose 5.6% to ¥42.5 billion. Total assets and net assets both increased, the equity ratio held steady at 33.9%, and cash and cash equivalents expanded, reflecting a solid balance sheet despite weaker operating cash flows.

The company raised its annual dividend to ¥66 per share for FY2026 and plans a further increase to ¥68 in FY2027, signaling continued shareholder returns. For the year to March 2027, Medipal forecasts modest sales and operating profit growth but expects ordinary profit and bottom-line earnings to decline, while recent portfolio reshaping through acquisitions and internal mergers suggests ongoing optimization of its group structure and consolidation scope.

The most recent analyst rating on (JP:7459) stock is a Hold with a Yen2700.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.

More about Medipal Holdings

Medipal Holdings is a Japan-based wholesaler focused on the distribution of pharmaceuticals, medical supplies and related healthcare products. Listed on the Tokyo Stock Exchange under code 7459, the company operates a nationwide logistics network serving medical institutions, pharmacies and other healthcare providers, positioning itself as a core player in Japan’s medical distribution infrastructure.

Average Trading Volume: 417,105

Technical Sentiment Signal: Buy

Current Market Cap: Yen505.9B

See more insights into 7459 stock on TipRanks’ Stock Analysis page.